Epigenetic modification boosts ovarian cancer vaccination

Lancet Oncol. 2014 Feb;15(2):e55.
No abstract available

Publication types

  • News

MeSH terms

  • Antigens, Neoplasm / immunology
  • Antigens, Neoplasm / therapeutic use*
  • Azacitidine / analogs & derivatives*
  • Azacitidine / therapeutic use
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Carcinoma, Ovarian Epithelial
  • Combined Modality Therapy
  • DNA Methylation / drug effects*
  • DNA Modification Methylases / antagonists & inhibitors
  • DNA Modification Methylases / metabolism
  • Decitabine
  • Enzyme Inhibitors / therapeutic use*
  • Epigenesis, Genetic / drug effects*
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Membrane Proteins / immunology
  • Membrane Proteins / therapeutic use*
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasms, Glandular and Epithelial / genetics
  • Neoplasms, Glandular and Epithelial / immunology
  • Neoplasms, Glandular and Epithelial / therapy*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Antigens, Neoplasm
  • CTAG1B protein, human
  • Cancer Vaccines
  • Enzyme Inhibitors
  • Membrane Proteins
  • Decitabine
  • DNA Modification Methylases
  • Azacitidine